Nodular Lymphocyte Predominant B-cell Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-04-13
Clinical Trial Update: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial [Phase 2]
A National Cancer Institute–sponsored Phase 2 trial (NORM) is evaluating rituximab versus mosunetuzumab in nodular lymphocyte-predominant ly…